Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-027-7 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
A NOAEC of 250 ppm (1060 mg/m3) is selected for inhalation exposure based on organ (liver, adrenals and kidneys) weight increases seen in the 90 day study with male and female F-344 rats.
For the oral route, a NOAEL of 125 mg/kg bw/day is selected based on increased adrenal (absolute and relative) and kidney (relative) weights at higher doses in male rats in the 28 day study.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 125 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEC
- 1 060 mg/m³
- Study duration:
- subchronic
- Species:
- rat
Additional information
Regarding the oral route, a subacute toxicity with rats is available. Five male and five female Sprague-Dawley rats were administered 0, 125, 500 or 1000 mg/kg bw TAME in corn oil by gavage (Daughtrey et al., 1995). The dose was given once daily, 7 days a week for a period of 29 days. The critical effects observed were an increased adrenal (absolute and relative) and kidney (relative) weight at 500 and 1000 mg/kg bw in males. The organ weight increases in the kidney and adrenals were not accompanied by any histopathological changes. Liver weights were not affected significantly. The NOAEL was set at 125 mg/kg bw/day.
For inhalation repeated dose toxicity, two 90 days studies are available, one with rats and one with mice (Huntingdon Life Sciences, 1997a/b). In addition, a subacute toxicity study with rats is also available (IIT Research Institute, 1992). The 90 days studies are considered key (longer exposure duration, lower NOAEC). In these studies the exposure concentrations were 250, 1500 and 2500 / 3500 ppm (1060, 6360, 10600 / 14840 mg/m3).
In mice, the critical effect was an increase in the labeling index of hepatocytes in high- and mid-exposure males and females and low-exposure females. There was microscopic evidence of centrilobular, hepatocellular hypertrophy in high- and mid-exposure males and females. Based on these findings, the NOAEC for male mice exposed to TAME was 250 ppm (1060 mg/m3); a NOAEC for female mice was not established by the study authors. However, given the absence of dose-response in the female liver proliferation findings and their transient nature, the EU concluded in their risk assessment report that the NOAEC can be set at 250 ppm (1060 mg/m3) for both males and females.
In rats, effects critical for setting the NOAEC were (relative) organ weights increases in male and female liver, adrenals and kidney. Increased absolute and relative adrenal weights in the 3500 and 1500 ppm males and females and 250 ppm males were explained by the investigators as a response to stress due to exposure to the test material. They did not consider this a direct effect of the test material because there were no microscopic lesions in the adrenals. Only male rats showed α-2µ-microglobulin-related cell proliferation of the kidney tubules, which could have contributed to the weight change in male kidneys at 3500 ppm. The increase in the female kidney weights at 3500 and 1500 ppm could not be explained by any toxicological phenomenon. After the 4-week recovery period, the high dose males and females had increased kidney to body weights, although the absolute and kidney to brain weights were comparable to control values.
The investigators set the NOAEC to 250 ppm (1060 mg/m3) for females based on the increased liver and kidney weights at 1500 ppm. Based on the liver weight increase in all dose groups, no NOAEC can be set for males. While liver weight increase is a typical form of adaptation and could be seen as non-adverse, it is more difficult to account for the adrenal or especially the kidney weight increases simply as adaptive. It is debatable whether, e.g., the adrenal organ weight increases with no adverse changes in microscopy or blood values can be discounted as “indirect” or “stress-related”. However, although there was an 8% increase in kidney/brain weight and a 10% increase in adrenal/brain weight in males at 250 ppm, this level was not considered as the LOAEC by the EU (conclusion from the EU risk assessment report). The weight increases were statistically significant only when presented as absolute weight or organ/brain weight values. Since the body weight of the low dose males also increased (+9%), a factor that may have played a contributing or confounding role, and since there was no histopathological damage present in these animals, the exposure level of 250 ppm (1060 mg/m3) was considered as a NOAEC.
Repeated dose toxicity: via oral route - systemic effects (target organ) glandular: adrenal gland; urogenital: kidneys
Repeated dose toxicity: inhalation - systemic effects (target organ) digestive: liver; glandular: adrenal gland; neurologic: central nervous system; urogenital: kidneys
Justification for classification or non-classification
In accordance with Directive 67/548/EEC and EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008, classification is not necessary for repeated dose toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.